共 45 条
- [31] Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trialANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (04)Zhang, LiLu, ShunCheng, YingHu, ZhihuangWu, Yi-LongChen, ZhiweiChen, GongyanLiu, XiaoqingYang, JinjiChen, JiaHuang, MeijuanTao, MinCheng, GangHuang, ChengZhou, CaicunZhang, WeiminZhao, HongSun, Yuping
- [32] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinomaANNALS OF ONCOLOGY, 2023, 34 : S1524 - S1525Ajani, J. A.Lordick, F.Bang, Y-J.Enzinger, P. C.Ilson, D. H.Shah, M. A.van Cutsem, E.Xu, R-H.Aprile, G.Xu, J.Pazo Cid, R. A.Kang, Y-K.Yang, J.Moran, D.Bhattacharya, P.Matsangou, M.Arozullah, A.Park, J. W.Shitara, K.
- [33] Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinomaANNALS OF ONCOLOGY, 2023, 34 : S1524 - S1524Lordick, F.Shah, M. A.Shitara, K.Ajani, J. A.Bang, Y-J.Enzinger, P. C.Ilson, D. H.van Cutsem, E.Gallego Plazas, J.Huang, J.Shen, L.Oh, S. C.Sunpaweravong, P.Soo, H. H. F.Turk, H. M.Park, J. W.Moran, D.Bhattacharya, P.Cao, Y. J.Xu, R-H.
- [34] Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinomaANNALS OF ONCOLOGY, 2023, 34 : S1321 - S1321Lordick, F.Shah, M. A.Shitara, K.Ajani, J. A.Bang, Y-J.Enzinger, P. C.Ilson, D. H.Van Cutsem, E.Plazas, J. GallegoHuang, J.Shen, L.Oh, S. C.Sunpaweravong, P.Soo, H. H. F.Turk, H. M.Park, J. W.Moran, D.Bhattacharya, P.Cao, Y. J.Xu, R-H.
- [35] KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib (ola) vs pembro plus chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBCANNALS OF ONCOLOGY, 2020, 31 : S1268 - S1268Saji, S.Cussac, A. LlombartAndre, F.Robson, M. E.Harbeck, N.Schmid, P.Cescon, D. W.Ahn, J. S.Nanda, R.Fan, L.Mejia, J. A.Karantza, V.Bardia, A.Rugo, H. S.
- [36] Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)Bendell, Johanna C.Tan, Benjamin R.Reeves, James AndrewXiong, HenrySomer, Bradley G.Lenz, Heinz-JosefHochster, Howard S.Scappaticci, FrankSommer, NicolasDay, Bann-moHurwitz, Herbert
- [37] Phase II randomized study of maintenance therapy with regorafenib (REGO) versus placebo after first-line platinum and fluoropyrimidines-based chemotherapy in HER2 negative locally advanced/metastatic gastric (GC) or gastroesophageal junction (GEJ) cancer: Results of a-MANTRA study (GOIRC-05-2016)JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Damato, AngelaBilancia, DomenicoIachetta, FrancescoStrippoli, AntoniaFiliali, FrancescaCasaretti, RossanaBernardini, IlariaBellotti, GiovannaFrassineti, Giovanni LucaDi Fabio, FrancescaAieta, MicheleGhidini, MicheleTrentin, ChiaraCardellino, Giovanni GerardoGervasi, ErikaRomagnani, AlessandraCinieri, SaverioNormanno, NicolaPinto, Carmine
- [38] Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nabpaclitaxel (nab-pac) as first-line ( 1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)CANCER RESEARCH, 2022, 82 (04)Hatem, SolimanHargis, JeffreyElias, AnthonyLee, ArielleSwart, RachelDahkil, ShakerDrakaki, AlexandraPhan, VuKass, FredericCobleigh, MelodyBabu, SanilTkaczuk, KatherineO'Connell, BrendaRoberts, JenniferZizlsperger, NoraHamilton, Erika
- [39] Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER22, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Shitara, KoheiVan Cutsem, EricLordick, FlorianEnzinger, Peter C.Ilson, David H.Shah, Manish A.Xu, Rui-HuaLonardi, SaraYamaguchi, KenseiHung, Yi-PingKukielka-Budny, BozenaBhattacharya, Pranob P.Matsangou, MariaLi, RanMoran, Diarmuid MartinRanganath, RadhikaPophale, RupeshAjani, Jaffer A.
- [40] Open-label, randomized, multicenter, phase II trial designed to compare the efficacy of CAPTEM combination versus FOLFIRI as second line treatment in patients (pts) who have progressed on or after first-line oxaliplatin-containing chemotherapy for advanced, MGMT methylated, RAS mutated colorectal cancer (CRC)JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Berenato, RosaPietrantonio, FilippoCaporale, MartaBossi, IlariaTomasello, GianlucaMosconi, StefaniaPaterno, EmanuelaBozzarelli, SilviaLongarini, RaffaellaGori, StefaniaZaniboni, AlbertoBertolini, Alessandro StefanoBergamo, FrancescaBarni, SandroAmatu, AlessioFagnani, DanieleZampino, M. GiuliaMorano, FedericaDi Bartolomeo, MariaDe Braud, Filippo G.